Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Shares Outstanding (Weighted Average) (2020 - 2026)

Immuneering's Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $64.7 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 81.99% to $64.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $64.7 million, a 81.99% increase, with the full-year FY2025 number at $44.0 million, up 46.8% from a year prior.
  • Shares Outstanding (Weighted Average) came in at $64.7 million for Q1 2026, up from $44.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $64.7 million in Q1 2026, with the low at $26.4 million in Q1 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $32.7 million across 5 years, with a median of $29.4 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 432.57% in 2022 and later increased 0.32% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $26.4 million in 2022, then rose by 7.69% to $28.4 million in 2023, then grew by 5.51% to $30.0 million in 2024, then soared by 46.8% to $44.0 million in 2025, then skyrocketed by 46.91% to $64.7 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for IMRX at $64.7 million in Q1 2026, $44.0 million in Q4 2025, and $39.7 million in Q3 2025.